Skip to content

Study · Animal study (in vivo) · mouse · 2024

13 results

The Role of Nicotinamide Mononucleotide Supplementation in Psoriasis Treatment.

Zhang Z, Cheng B, Du W, Zeng M, He K, Yin T, Shang S, Su T, Han D, Gan X, Wang Z, Liu M, Wang M, Liu J, Zheng Y

Antioxidants (Basel, Switzerland)1 Feb 2024Cited by 13 (Europe PMC)

PMID38397784 (opens in a new tab)PMCIDPMC10886094 (opens in a new tab)DOI10.3390/antiox13020186 (opens in a new tab)PepBankPUB-38397784
Download PDFPubMedAsk about this study
Jump to 13 results

Summary

Psoriasis is one of several chronic inflammatory skin diseases with a high rate of recurrence, and its pathogenesis remains unclear. Nicotinamide mononucleotide (NMN), as an important precursor of nicotinamide adenine dinucleotide (NAD+), has been reported to be a promising agent in treating various diseases, its positive effects including those induced via its anti-inflammatory and antioxidant properties. For this reason, we have aimed to explore the possible role of NMN in the treatment of psoriasis. Psoriasis models were constructed with imiquimod (IMQ) stimulation for 5 days in vivo and with M5 treatment in keratinocyte cell lines in vitro. NMN treatment during the IMQ application period markedly attenuated excess epidermal proliferation, splenomegaly, and inflammatory responses. According to GEO databases, Sirtuin1 (SIRT1) levels significantly decreased in psoriasis patients' lesion tissues; this was also the case in the IMQ-treated mice, while NMN treatment reversed the SIRT1 decline in the mouse model. Moreover, NMN supplementation also improved the prognoses of the mice after IMQ stimulation, compared to the untreated group with elevated SIRT1 levels. In HEKa and HaCaT cells, the co-culturing of NMN and M5 significantly decreased the expression levels of proinflammation factors, the phosphorylation of NF-κB, stimulator of interferon genes (STING) levels, and reactive oxygen species levels. NMN treatment also recovered the decrease in mitochondrial membrane potential and respiration ability and reduced mtDNA in the cytoplasm, leading to the inhibition of autoimmune inflammation. The knockdown of SIRT1 in vitro eliminated the protective and therapeutic effects of NMN against M5. To conclude, our results indicate that NMN protects against IMQ-induced psoriatic inflammation, oxidative stress, and mitochondrial dysfunction by activating the SIRT1 pathway.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study13

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In IMQ-treated mice, NMN attenuated excess epidermal proliferation.

    In plain wordsIn mice with induced psoriasis, NMN reduced excessive skin cell multiplication.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseEpidermal proliferation
    Study

    mousen: not reported in source

    IMQ-induced psoriasis
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NMN treatment during the IMQ application period markedly attenuated excess epidermal proliferation, splenomegaly, and inflammatory responses.
    1 context sentence
    Summary · context
    Psoriasis models were constructed with imiquimod (IMQ) stimulation for 5 days in vivo and with M5 treatment in keratinocyte cell lines in vitro.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In IMQ-treated mice, NMN attenuated splenomegaly.

    In plain wordsIn mice with induced psoriasis, NMN reduced spleen enlargement.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseSplenomegaly
    Study

    mousen: not reported in source

    IMQ-induced psoriasis
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NMN treatment during the IMQ application period markedly attenuated excess epidermal proliferation, splenomegaly, and inflammatory responses.
    1 context sentence
    Summary · context
    Psoriasis models were constructed with imiquimod (IMQ) stimulation for 5 days in vivo and with M5 treatment in keratinocyte cell lines in vitro.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In IMQ-treated mice, NMN attenuated inflammatory responses.

    In plain wordsIn mice with induced psoriasis, NMN reduced inflammatory responses.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseInflammatory responses
    Study

    mousen: not reported in source

    IMQ-induced psoriasis
    Outcome group
    Inflammation markers · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NMN treatment during the IMQ application period markedly attenuated excess epidermal proliferation, splenomegaly, and inflammatory responses.
    1 context sentence
    Summary · context
    Psoriasis models were constructed with imiquimod (IMQ) stimulation for 5 days in vivo and with M5 treatment in keratinocyte cell lines in vitro.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In IMQ-treated mice, NMN reversed the decline in SIRT1 levels.

    In plain wordsIn mice with induced psoriasis, NMN restored SIRT1 levels.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseSIRT1 levels
    Study

    mousen: not reported in source

    IMQ-induced psoriasis
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    According to GEO databases, Sirtuin1 (SIRT1) levels significantly decreased in psoriasis patients' lesion tissues; this was also the case in the IMQ-treated mice, while NMN treatment reversed the SIRT1 decline in the mouse model.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    After IMQ stimulation, NMN improved mouse prognoses with elevated SIRT1 levels compared with the untreated group.

    In plain wordsIn mice after psoriasis induction, NMN improved prognosis compared with untreated mice.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreasePrognosis
    Study

    mousen: not reported in source

    IMQ-induced psoriasis
    Comparator
    Untreated group
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, NMN supplementation also improved the prognoses of the mice after IMQ stimulation, compared to the untreated group with elevated SIRT1 levels.
  6. 06LabIn vitro (cells)Efficacy outcome

    In M5-treated HEKa and HaCaT cells, NMN reduced proinflammatory factor expression.

    In plain wordsIn cells treated with M5, NMN reduced inflammatory factor expression.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseProinflammatory factor expression
    Study

    n: not reported in source

    M5-treated HEKa and HaCaT cells
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In HEKa and HaCaT cells, the co-culturing of NMN and M5 significantly decreased the expression levels of proinflammation factors, the phosphorylation of NF-κB, stimulator of interferon genes (STING) levels, and reactive oxygen species levels.
  7. 07LabIn vitro (cells)Mechanism

    In M5-treated HEKa and HaCaT cells, NMN reduced NF-κB phosphorylation.

    In plain wordsIn cells treated with M5, NMN reduced NF-κB phosphorylation.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseNF-κB phosphorylation
    Study

    n: not reported in source

    M5-treated HEKa and HaCaT cells
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In HEKa and HaCaT cells, the co-culturing of NMN and M5 significantly decreased the expression levels of proinflammation factors, the phosphorylation of NF-κB, stimulator of interferon genes (STING) levels, and reactive oxygen species levels.
  8. 08LabIn vitro (cells)Mechanism

    In M5-treated HEKa and HaCaT cells, NMN reduced STING levels.

    In plain wordsIn cells treated with M5, NMN reduced STING levels.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseSTING levels
    Study

    n: not reported in source

    M5-treated HEKa and HaCaT cells
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In HEKa and HaCaT cells, the co-culturing of NMN and M5 significantly decreased the expression levels of proinflammation factors, the phosphorylation of NF-κB, stimulator of interferon genes (STING) levels, and reactive oxygen species levels.
  9. 09LabIn vitro (cells)Efficacy outcome

    In M5-treated HEKa and HaCaT cells, NMN reduced reactive oxygen species levels.

    In plain wordsIn cells treated with M5, NMN reduced reactive oxygen species levels.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseReactive oxygen species
    Study

    n: not reported in source

    M5-treated HEKa and HaCaT cells
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In HEKa and HaCaT cells, the co-culturing of NMN and M5 significantly decreased the expression levels of proinflammation factors, the phosphorylation of NF-κB, stimulator of interferon genes (STING) levels, and reactive oxygen species levels.
  10. 10LabIn vitro (cells)Efficacy outcome

    In the psoriasis cell model, NMN restored mitochondrial membrane potential.

    In plain wordsIn cells used to model psoriasis, NMN restored mitochondrial membrane potential.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseMitochondrial membrane potential
    Study

    n: not reported in source

    M5-treated keratinocytes
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NMN treatment also recovered the decrease in mitochondrial membrane potential and respiration ability and reduced mtDNA in the cytoplasm, leading to the inhibition of autoimmune inflammation.
    1 context sentence
    Summary · context
    In HEKa and HaCaT cells, the co-culturing of NMN and M5 significantly decreased the expression levels of proinflammation factors, the phosphorylation of NF-κB, stimulator of interferon genes (STING) levels, and reactive oxygen species levels.
  11. 11LabIn vitro (cells)Efficacy outcome

    In the psoriasis cell model, NMN restored respiration ability.

    In plain wordsIn cells used to model psoriasis, NMN restored cellular respiration.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseRespiration ability
    Study

    n: not reported in source

    M5-treated keratinocytes
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NMN treatment also recovered the decrease in mitochondrial membrane potential and respiration ability and reduced mtDNA in the cytoplasm, leading to the inhibition of autoimmune inflammation.
    1 context sentence
    Summary · context
    In HEKa and HaCaT cells, the co-culturing of NMN and M5 significantly decreased the expression levels of proinflammation factors, the phosphorylation of NF-κB, stimulator of interferon genes (STING) levels, and reactive oxygen species levels.
  12. 12LabIn vitro (cells)Mechanism

    In the psoriasis cell model, NMN reduced cytoplasmic mtDNA.

    In plain wordsIn cells used to model psoriasis, NMN reduced mitochondrial DNA in the cytoplasm.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseCytoplasmic mtDNA
    Study

    n: not reported in source

    M5-treated keratinocytes
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NMN treatment also recovered the decrease in mitochondrial membrane potential and respiration ability and reduced mtDNA in the cytoplasm, leading to the inhibition of autoimmune inflammation.

Studies that did not test the peptide alone1

In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking NMN (nicotinamide mononucleotide).

  1. 13LabNot a test of NMN (nicotinamide mononucleotide) aloneIn vitro (cells)Mechanism

    In vitro SIRT1 knockdown eliminated NMN protective and therapeutic effects against M5.

    In plain wordsIn cells, reducing SIRT1 expression removed NMN protection against M5.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    Not applicableSIRT1 dependence of protection
    Study

    n: not reported in source

    SIRT1-knockdown M5-treated cells
    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    The knockdown of SIRT1 in vitro eliminated the protective and therapeutic effects of NMN against M5.

    In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.